ES2706948T3 - Formas cristalinas de complejo supramolecular trisódico que comprende valsartán y AHU-377 y procedimientos de las mismas - Google Patents

Formas cristalinas de complejo supramolecular trisódico que comprende valsartán y AHU-377 y procedimientos de las mismas Download PDF

Info

Publication number
ES2706948T3
ES2706948T3 ES15843405T ES15843405T ES2706948T3 ES 2706948 T3 ES2706948 T3 ES 2706948T3 ES 15843405 T ES15843405 T ES 15843405T ES 15843405 T ES15843405 T ES 15843405T ES 2706948 T3 ES2706948 T3 ES 2706948T3
Authority
ES
Spain
Prior art keywords
crystalline form
ylmethyl
biphenyl
heart failure
ahu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15843405T
Other languages
English (en)
Spanish (es)
Inventor
Minhua Chen
Yanfeng Zhang
Chaohui Yang
Xiaoyu Zhang
Jiaoyang Li
Peng Wang
Pixu Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUZHOU PENGXU PHARMATECH CO Ltd
Crystal Pharmatech Co Ltd
Original Assignee
SUZHOU PENGXU PHARMATECH CO Ltd
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55582176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2706948(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SUZHOU PENGXU PHARMATECH CO Ltd, Crystal Pharmatech Co Ltd filed Critical SUZHOU PENGXU PHARMATECH CO Ltd
Application granted granted Critical
Publication of ES2706948T3 publication Critical patent/ES2706948T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES15843405T 2014-12-08 2015-12-08 Formas cristalinas de complejo supramolecular trisódico que comprende valsartán y AHU-377 y procedimientos de las mismas Active ES2706948T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462089225P 2014-12-08 2014-12-08
PCT/US2015/064432 WO2016049663A1 (en) 2014-12-08 2015-12-08 Crystalline forms of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof

Publications (1)

Publication Number Publication Date
ES2706948T3 true ES2706948T3 (es) 2019-04-01

Family

ID=55582176

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15843405T Active ES2706948T3 (es) 2014-12-08 2015-12-08 Formas cristalinas de complejo supramolecular trisódico que comprende valsartán y AHU-377 y procedimientos de las mismas

Country Status (16)

Country Link
US (2) US9957240B2 (enExample)
EP (2) EP3443960A1 (enExample)
JP (3) JP2017537120A (enExample)
CN (3) CN110938042B (enExample)
AU (1) AU2015319831B2 (enExample)
CA (1) CA2970192C (enExample)
DK (1) DK3229799T3 (enExample)
ES (1) ES2706948T3 (enExample)
HU (1) HUE043014T2 (enExample)
IL (2) IL252740A0 (enExample)
MX (1) MX383336B (enExample)
PL (1) PL3229799T3 (enExample)
PT (1) PT3229799T (enExample)
SI (1) SI3229799T1 (enExample)
TR (1) TR201900360T4 (enExample)
WO (1) WO2016049663A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
AU2015319831B2 (en) 2014-12-08 2019-02-14 Crystal Pharmatech Co., Ltd. Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof
EP3307720A1 (en) * 2015-06-12 2018-04-18 Teva Pharmaceuticals International GmbH Solid state forms of trisodium valsartan: sacubitril
CN105037289B (zh) * 2015-07-17 2017-08-22 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型
WO2017012600A1 (en) * 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106854187B (zh) * 2015-12-08 2020-04-14 苏州晶云药物科技股份有限公司 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
CN105753733B (zh) * 2016-04-15 2019-06-18 苏州晶云药物科技股份有限公司 Ahu377的晶型及其制备方法与用途
US10683260B2 (en) * 2016-09-07 2020-06-16 Nanjing Noratech Pharmaceuticals Co., Ltd. Crystalline form of sacubitril sodium salt
US10857132B2 (en) 2016-10-10 2020-12-08 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
CN110713465A (zh) * 2017-01-03 2020-01-21 上海博志研新药物技术有限公司 ARB-NEPi复合物、晶型、制备方法及应用
CN108299323A (zh) * 2017-01-11 2018-07-20 上海迪赛诺药业股份有限公司 一种抗心衰共晶化合物的新晶型
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
WO2019239432A1 (en) 2018-06-14 2019-12-19 Cipla Limited Trisodium sacubitril valsartan complex and hot-melt extruded pharmaceutical composition comprising thereof
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN111253330B (zh) * 2020-02-29 2023-01-24 广州白云山天心制药股份有限公司 沙坦类药物的新晶型及其制备方法和用途
KR102858594B1 (ko) * 2020-10-08 2025-09-11 한미약품 주식회사 사쿠비트릴 및 발사르탄 나트륨염을 포함하는 경구용 고형제제
CN115745904A (zh) * 2022-09-29 2023-03-07 浙江美诺华药物化学有限公司 一种沙库巴曲缬沙坦钠共晶物的制备方法
CN118141930A (zh) * 2024-03-26 2024-06-07 迪沙药业集团有限公司 沙坦类药物组合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3796763B2 (ja) * 1994-04-01 2006-07-12 東ソー株式会社 結晶形２，２−ビス（３，５−ジブロモ−４−ジブロモプロポキシフェニル）プロパン及びその製造方法
EP1467728B1 (en) * 2002-01-17 2007-08-22 Novartis AG Pharmaceutical compositions comprising valsartan and nep inhibitors
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
FR2897060B1 (fr) * 2006-02-08 2008-07-25 Sanofi Aventis Sa Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
US7994238B2 (en) * 2007-09-04 2011-08-09 General Electric Company Article and associated method
DK2217205T3 (en) 2007-11-06 2015-05-11 Novartis Ag DOUBLE-ACTING PHARMACEUTICAL COMPOSITIONS BASED ON SUPER STRUCTURES OF ANGIOTENSINRECEPTORANTAGONIST / blocker (ARB) AND NEUTRAL endopeptidase (NEP) INHIBITOR
MA34483B1 (fr) 2010-08-24 2013-08-01 Novartis Ag Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante
JP5809367B2 (ja) * 2013-04-24 2015-11-10 あすか製薬株式会社 レボノルゲストレルの結晶多形α及びその製造方法
AU2015319831B2 (en) 2014-12-08 2019-02-14 Crystal Pharmatech Co., Ltd. Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
EP3307720A1 (en) 2015-06-12 2018-04-18 Teva Pharmaceuticals International GmbH Solid state forms of trisodium valsartan: sacubitril
CN105037289B (zh) * 2015-07-17 2017-08-22 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型
CN106854187B (zh) * 2015-12-08 2020-04-14 苏州晶云药物科技股份有限公司 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法

Also Published As

Publication number Publication date
US9957240B2 (en) 2018-05-01
CN105873586A (zh) 2016-08-17
EP3229799A1 (en) 2017-10-18
CA2970192A1 (en) 2016-03-31
US10508087B2 (en) 2019-12-17
HUE043014T2 (hu) 2019-07-29
CN105873586B (zh) 2019-09-13
CN110938042B (zh) 2022-12-13
EP3229799B1 (en) 2018-10-17
PT3229799T (pt) 2019-01-29
US20170362189A1 (en) 2017-12-21
IL276233B1 (en) 2023-03-01
CN110938042A (zh) 2020-03-31
JP2017537120A (ja) 2017-12-14
PL3229799T3 (pl) 2019-05-31
CN110922366A (zh) 2020-03-27
EP3443960A1 (en) 2019-02-20
AU2015319831B2 (en) 2019-02-14
IL252740A0 (en) 2017-08-31
US20180201589A1 (en) 2018-07-19
CA2970192C (en) 2020-08-04
JP2018168180A (ja) 2018-11-01
MX383336B (es) 2025-03-11
MX2017007426A (es) 2018-04-20
DK3229799T3 (en) 2019-02-11
JP2020203936A (ja) 2020-12-24
SI3229799T1 (sl) 2019-03-29
IL276233B2 (en) 2023-07-01
AU2015319831A1 (en) 2017-07-20
TR201900360T4 (tr) 2019-02-21
EP3229799A4 (en) 2017-10-18
WO2016049663A1 (en) 2016-03-31
CN110922366B (zh) 2023-02-03
IL276233A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
ES2706948T3 (es) Formas cristalinas de complejo supramolecular trisódico que comprende valsartán y AHU-377 y procedimientos de las mismas
JP6313286B2 (ja) 短時間作用型ベンゾジアゼピンを含む組成物
ES3014022T3 (en) Angiotensin ii receptor antagonist metabolite and nep inhibitor composite, and preparation method thereof
WO2016051393A2 (en) Crystalline form iv of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
ES2704198T3 (es) Formas cristalinas de lesinurad
JP2022506062A (ja) 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用
CN102421742B (zh) 3-戊基苯乙酸的盐及其药物用途
JP2023550428A (ja) インテグリン阻害剤およびその使用
ES2878107T3 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
BR112021012226A2 (pt) Composições de esparsentano amorfo
CN103694172A (zh) 含氮杂芳基化合物的衍生物
JP2020500936A (ja) ピリジノイルピペリジン５−ｈｔ１ｆアゴニストに関する組成物および方法
CN103917514B (zh) 治疗包括骨髓增生性肿瘤和慢性骨髓性白血病在内的与转导素β样蛋白1(TBL1)活性相关的疾病和病症的方法
US10220072B2 (en) Mesalamine for the treatment of cancer
US20210137953A1 (en) Inhibitors of Mcl-1 and Akt Binding, Pharmaceutical Compositions, and Uses in Treating Cancer
US20240342157A1 (en) Bak activators, pharmaceutical compositions, and uses in treating cancer
KR20190121784A (ko) 경구 투여용 갈륨 (iii) 복합체 조성물
KR20240155526A (ko) 엔잘루타마이드를 포함하는 무정형 고체 분산체, 그를 포함하는 경구 투여용 약제학적 제제
WO2025218795A1 (zh) 一种药物组合物及其应用
WO2025218797A1 (zh) 一种胶囊或固体制剂及其应用
BR122025019564A2 (pt) Dispersão seca por pulverização, composição para sua formulação e método de fabricação da mesma, forma de dosagem sólida e seu método de fabricação, e uso de um inibidor de piridazinona trpc5 para tratar dor, ansiedade ou depressão